Literature DB >> 26154870

Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures.

Yanping Li1, Yangyang Zhou1, Jiayu Jiang1, Xinyi Wang1, Yao Fu1, Tao Gong1, Xun Sun1, Zhirong Zhang1.   

Abstract

The first molecular insights into how prodrugs modified with ethanolamine-related structures target the brain were generated using an in vitro BBB model and in situ perfusion technique. Prodrugs were delivered safely and efficiently to the brain through tight interaction with the anionic membrane of brain capillary endothelial cells, observed as a shift in zeta potential, followed by uptake into the cells. Prodrugs III and IV carrying primary and secondary amine modifications appeared to enter the brain via energy-independent passive diffusion. In contrast, besides the passive diffusion, prodrugs I and II carrying tertiary amine modifications also appeared to enter via an active process that was energy and pH dependent but was independent of sodium or membrane potential. This active process involved, at least in part, the pyrilamine-sensitive H(+)/OC antiporter, for which the N,N-diethyl-based compound II showed a much lower affinity than the N,N-dimethyl-based compound I, likely due to steric hindrance. These new insights into brain-targeting mechanisms may help guide efforts to design new prodrugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26154870      PMCID: PMC4671119          DOI: 10.1038/jcbfm.2015.160

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  36 in total

Review 1.  Modern methods for delivery of drugs across the blood-brain barrier.

Authors:  Yan Chen; Lihong Liu
Journal:  Adv Drug Deliv Rev       Date:  2011-11-28       Impact factor: 15.470

2.  Crossing the blood-brain barrier: are we getting it right?

Authors:  W M. Pardridge
Journal:  Drug Discov Today       Date:  2001-01-01       Impact factor: 7.851

Review 3.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

Review 4.  Role of organic cation transporters (OCTs) in the brain.

Authors:  Thomas Couroussé; Sophie Gautron
Journal:  Pharmacol Ther       Date:  2014-09-22       Impact factor: 12.310

5.  Carrier-mediated transport of H1-antagonist at the blood-brain barrier: a common transport system of H1-antagonists and lipophilic basic drugs.

Authors:  M Yamazaki; T Terasaki; K Yoshioka; O Nagata; H Kato; Y Ito; A Tsuji
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 6.  Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

Authors:  Carol Kilkenny; William J Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  PLoS Biol       Date:  2010-06-29       Impact factor: 8.029

7.  Transport characteristics of tramadol in the blood-brain barrier.

Authors:  Atsushi Kitamura; Kei Higuchi; Takashi Okura; Yoshiharu Deguchi
Journal:  J Pharm Sci       Date:  2014-08-29       Impact factor: 3.534

8.  Carrier-mediated transport of H1-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures.

Authors:  M Yamazaki; T Terasaki; K Yoshioka; O Nagata; H Kato; Y Ito; A Tsuji
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

9.  Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone.

Authors:  Takashi Okura; Asami Hattori; Yusuke Takano; Takenori Sato; Margareta Hammarlund-Udenaes; Tetsuya Terasaki; Yoshiharu Deguchi
Journal:  Drug Metab Dispos       Date:  2008-07-07       Impact factor: 3.922

10.  Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug.

Authors:  W M Pardridge; R Sakiyama; G Fierer
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

View more
  6 in total

1.  Sobetirome prodrug esters with enhanced blood-brain barrier permeability.

Authors:  Andrew T Placzek; Skylar J Ferrara; Meredith D Hartley; Hannah S Sanford-Crane; J Matthew Meinig; Thomas S Scanlan
Journal:  Bioorg Med Chem       Date:  2016-09-16       Impact factor: 3.641

2.  Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.

Authors:  Skylar J Ferrara; J Matthew Meinig; Andrew T Placzek; Tapasree Banerji; Peter McTigue; Meredith D Hartley; Hannah S Sanford-Crane; Tania Banerji; Dennis Bourdette; Thomas S Scanlan
Journal:  Bioorg Med Chem       Date:  2017-03-23       Impact factor: 3.641

3.  From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease.

Authors:  Claudia Albertini; Marina Naldi; Sabrina Petralla; Silvia Strocchi; Daniela Grifoni; Barbara Monti; Manuela Bartolini; Maria Laura Bolognesi
Journal:  Molecules       Date:  2021-02-19       Impact factor: 4.411

Review 4.  Microemulsion-Based Media in Nose-to-Brain Drug Delivery.

Authors:  Anna Froelich; Tomasz Osmałek; Barbara Jadach; Vinam Puri; Bozena Michniak-Kohn
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

5.  Substrates of the Human Brain Proton-Organic Cation Antiporter and Comparison with Organic Cation Transporter 1 Activities.

Authors:  David A Doetsch; Salim Ansari; Ole Jensen; Lukas Gebauer; Christof Dücker; Jürgen Brockmöller; Alexandra Sachkova
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

Review 6.  Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations.

Authors:  Anna Gliszczyńska; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.